Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma

References

• Lianes P, Remon J, Bover I, et al. SEOM guidelines for the treatment of malignant pleural mesothelioma. Clin Transl Oncol. 2011;119:514–518.
   Google Scholar
• Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesothelioma in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20:935–944.
   PubMed Web of Science ®Google Scholar
• Zucali PA, De Vincenzo F, Simonelli M. Santoro A: future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2009;9:453–467.
   PubMed Web of Science ®Google Scholar
• Shersher DD, Liptay MJ. Multimodality treatment of pleural mesothelioma. Surg Oncol Clin N Am. 2013;22:345–355.
   PubMed Web of Science ®Google Scholar
• Singhal S, Kaiser LR. Malignant mesothelioma: options for management. Surg Clin N Am. 2002;82:797–831.
   PubMed Web of Science ®Google Scholar
• Rusch V, Baldini EH, Bueno R, et al. The role of cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145:909–910.
   PubMed Web of Science ®Google Scholar
• Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association for the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol. 2012;7:1631–1639.
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of literature with meta-analysis. Lung Cancer. 2002;38:111–121.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
   PubMed Web of Science ®Google Scholar
• Zalcman M, Mazieres J, Greiller L, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–1414.
   PubMed Web of Science ®Google Scholar
• Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status and cell type detrmine post-operative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.
   PubMed Web of Science ®Google Scholar
• Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:149–153.
   PubMedGoogle Scholar
• Ried M, Potzger T, Braune N, et al. Local and systemic exposure of cisplatin during hypertermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol. 2013;107:735–740.
   PubMed Web of Science ®Google Scholar
• De Perrot M, Feld R, Cho BC, et al. Trimodality therapywith induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–1418.
   PubMed Web of Science ®Google Scholar
• Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013.
   PubMed Web of Science ®Google Scholar
• Pasello G, Marulli G, Polo V, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res. 2012;32:5393–5400.
   PubMed Web of Science ®Google Scholar
• Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:870–875. Discussion 876.
   PubMed Web of Science ®Google Scholar
• Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentrre trial. Eur Resp J. 2010;36:1362–1369.
   PubMed Web of Science ®Google Scholar
• Rea F, Favaretto A, Marulli G, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22.
   Google Scholar
• Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–295.
   PubMed Web of Science ®Google Scholar
• Weder W, Ketenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–3457.
   PubMed Web of Science ®Google Scholar
• Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:737–743.
   PubMed Web of Science ®Google Scholar
• Okada M, Mimura T, Ohbayashi C, et al. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg. 2008;7:102–106.
   PubMedGoogle Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. Lancet Oncol. 2011;12:763–772.
   PubMed Web of Science ®Google Scholar
• Weder W, Stahel RA, Bernard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–1202.
   PubMed Web of Science ®Google Scholar
• Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer. 2012;77:151–155.
   PubMed Web of Science ®Google Scholar
• Trousse DS, Avaro JP, D’Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009;36:759–763.
   PubMed Web of Science ®Google Scholar
• Bille A, Belcher E, Raubenheimer H, et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals. Gen Thorac Cardiovasc Surg. 2012;60:289–296.
   PubMedGoogle Scholar
• Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57:89–95.
   PubMed Web of Science ®Google Scholar
• Bece A, Tin MM, Martin D, et al. Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: toxicity and outcomes at an Australian institution. J Med Imaging Radiat Oncol. 2015;59:355–362.
   PubMed Web of Science ®Google Scholar
• Chance WW, Rice DC, Allen PK, et al. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015;91:149–156.
   PubMed Web of Science ®Google Scholar
• Thieke C, Nicolay NH, Sterzing F, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity modulated radiotherapy. Radiat Oncol. 2015;10:267.
   PubMed Web of Science ®Google Scholar
• Lee TT, Everett DL, Shu HG, et al. Radical pleurectomy/decortication ad intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–1189.
   PubMed Web of Science ®Google Scholar
• Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–1693.
   PubMed Web of Science ®Google Scholar
• Gupta V, Mychalczak B, Krug LM, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–1052.
   PubMed Web of Science ®Google Scholar
• Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol. 2009;4:746–750.
   PubMed Web of Science ®Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238–245.
   PubMed Web of Science ®Google Scholar
• Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326.
   PubMed Web of Science ®Google Scholar
• Luckraz H, Rahman M, Patel N, et al. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:552–556.
   PubMed Web of Science ®Google Scholar
• Baldini EH, Richards WG, Gill RR, et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015;149:1374–1381.
   PubMed Web of Science ®Google Scholar
• Lucchi M, Chella A, Melfi F, et al. A phase II study of intrapleural immune-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529–535.
   PubMed Web of Science ®Google Scholar
• Minatel E, Trovo M, Bearz A, et al. Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure and prognostic factor. Int J Radiation Oncol Biol Phys. 2015;93:606–613.
   PubMed Web of Science ®Google Scholar
• Miles EF, Larrier NA, Kelsey CR, et al. Intensity modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys. 2008;71:1143–1150.
   PubMed Web of Science ®Google Scholar
• Van Sandick JW, Kappers I, Baas P, et al. Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience. Ann Surg Oncol. 2008;15:1757–1764.
   PubMed Web of Science ®Google Scholar
• Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/Decortication, hypertermic pleural lavage with povidone-iodine, prophylatyc radiotherapy and systemic chemotherapy in patient with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149:558–565.
   PubMed Web of Science ®Google Scholar
• Bedirhan MA, Cansever L, Demir A, et al. Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? J Thorac Dis. 2013;5:446–454.
   PubMed Web of Science ®Google Scholar
• Friedberg JS, Simone CB, Culligan MJ 2nd, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103:912–919.
   PubMed Web of Science ®Google Scholar
• Nakas A, von Meyenfeldt E, Lau K, et al. Long-term results after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41:1031–1036.
   PubMed Web of Science ®Google Scholar
• Bolukbas S, Manegold C, Eberlein M, et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011;71:75–81.
   PubMed Web of Science ®Google Scholar
• Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hypertermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–411.
   PubMed Web of Science ®Google Scholar
• Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138:619–624.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hypertermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroentero Res Pract. 2012.
   Web of Science ®Google Scholar
• Tonoli S, Vitali P, Scotti V, et al. Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma prospective analysis of a multi-institutional series. Radiother Oncol. 2011;101:311–315.
   PubMed Web of Science ®Google Scholar
• Patel PR, Yoo S, Broadwater G, et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiation Oncol Biol Phys. 2012;83:362–368.
   PubMed Web of Science ®Google Scholar
• Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007;68:1366–1374.
   PubMed Web of Science ®Google Scholar
• Baas P. Chemotherapy for malignant pleural mesothelioma. Lung Cancer. 2005;49:S61–4.
   PubMed Web of Science ®Google Scholar
• Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2003;21:2629–2630.
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889.
   PubMed Web of Science ®Google Scholar
• Marulli G, Rea F, Nicotra S, et al. Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. Eur J Cardioth Surg. 2010;37:1464–1469.
   PubMed Web of Science ®Google Scholar
• Bech C, Sorensen JB. Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report. J Thorac Oncol. 2010;5:735–740.
   PubMed Web of Science ®Google Scholar
• Rimner A, Zauderer MJ, Gomez DR, et al. Phase II study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with Malignant Pleural Mesothelioma. J Clin Oncol. 2016;34:2761–2768.
   PubMed Web of Science ®Google Scholar
• Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640–645.
   PubMed Web of Science ®Google Scholar
• Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomized, international, multicenter phase 2 trial. Lancet Oncol. 2015;16:1651–1658.
   PubMed Web of Science ®Google Scholar
• Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9:397–402.
   PubMed Web of Science ®Google Scholar
• Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res. 1996;81:193–211.
   PubMedGoogle Scholar
• Sugarbaker DJ, Gill RR, Yeap BY, et al. Hypertermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Sur. 2013;145:955–963.
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Okada M, Tanaka F, et al. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int J Clin Oncol. 2016;21:523–530.
   PubMed Web of Science ®Google Scholar